Prevent Colon Cancer with Our Protective Diet Tips

Prevent Colon Cancer with Our Protective Diet Tips
Prevent Colon Cancer with Our Protective Diet Tips

The best cancer treatment can take place without even being diagnosed with the disease. Be proactive with diet and lifestyle changes to reduce your chances of developing colon cancer.

Tips to Prevent Colon Cancer

Dr. Charles Fuchs is the director of Yale Cancer Center. He recently appeared on local TV to promote Colon Cancer Awareness Month by offering these helpful tips to lower your risk:

– According to a recent Yale study, eating nuts can reduce the risk of colon cancer recurrence. More than 800 colon cancer patients completed a questionnaire about diet and lifestyle, and the responses showed that those who ate nuts regularly had a corresponding increase in their chances of a cure.

– Maintain a healthy weight. Centers for Disease Control and Prevention (CDC) has reported that obesity-related cancers account for approximately 40 percent of all cancer diagnoses in the U.S. Limiting the amount of red meat in your diet can make a big difference.

– Avoid smoking and excessive alcohol consumption. Smoking is the leading preventable cause of cancer, and according to the National Cancer Institute, even moderate drinking is associated with a higher risk of colorectal cancer.

Exercise regularly. Scientists believe physical activity can reduce the amount of time that harmful compounds are in the gastrointestinal tract.

– Get screened for colon cancer. Doctors recommend that adults 50 and over receive a colonoscopy every 10 years.

Integrative Cancer Treatment at Issels®

Nutritional immunotherapy is only one component of our integrative cancer treatment programs. Contact us to learn more about our comprehensive non-toxic therapies that boost the ability of your body’s own immune system to fight cancer.

Coley’s Toxin – the First Immunotherapy?

Coley's Toxin - the First Immunotherapy?
Coley’s Toxin – the First Immunotherapy?

When it comes to cancer treatment, immunotherapy is a hot buzzword right now, but it may not be as new as it seems. Many scientists believe that the first immunotherapy treatments date back to the late 1800s.

Coley’s Toxins: The Original Immunotherapy?

William Coley, a surgeon in turn-of-the-century New York, made a peculiar discovery about one of his patients. Fred Stein, who had been diagnosed with cancer, began making a recovery after contracting a serious infection.

Dr. Coley thought that perhaps bacteria from the infection jump-started Stein’s immune system, causing it to attack the tumors. This experience inspired the doctor to begin treating inoperable cancer patients with bacterial injections that came to be known as Coley’s toxins.

While Coley’s treatments did achieve some success, there was little documentation to support his findings. As a result, the doctor’s peers continued to favor radiation and chemotherapy as cancer treatments of choice.

A Man Ahead of His Time

For all intents and purposes, Dr. Coley’s methods died with him in 1936. Now, more than 80 years later, immunotherapy cancer treatment is “here to stay,” according to Jill O’Donnell-Tormey, chief executive of the Cancer Research Institute.

Immunotherapies known as checkpoint inhibitors are some of the top-selling drugs around the world. Checkpoint inhibitors follow Dr. Coley’s principle of boosting the body’s own immune response.

Dr. Josef M. Issels: A Pioneer of Immunotherapy

We’re proud to carry on the legacy of our founder, Dr. Josef M. Issels, who was also an early proponent of immunotherapy cancer treatment. Contact Issels® for more information about our individually created immunotherapy programs.

UCLA Research Shows Chimeric Antigen Receptors May Boost Immune System Response to Fight Cancer

UCLA Research Shows Chimeric Antigen Receptors May Boost Immune System Response to Fight Cancer
UCLA Research Shows Chimeric Antigen Receptors May Boost Immune System Response to Fight Cancer

Tumors have a number of ways to avoid detection and attack by the body’s immune system, making them difficult to eliminate. In a victory for cancer immunotherapy, scientists have created a synthetic protein with the ability to reverse these defenses.

Overcoming Safeguards of Tumor Cells

Most diseased cells carry proteins called antigens that trigger a response from T cells in the immune system, resulting in neutralization of the threat. In contrast, tumor cells secrete immunosuppressive cytokines, and these soluble proteins disable the immune response from T cells.

Chimeric antigen receptor (CAR) T-cell therapy, which received FDA approval in 2017, has been successfully used to treat blood cancers such as leukemia. Unfortunately, these therapies have not had a similar effect on solid tumors.

Making Cancer Work Against Itself

Building on the principle of CARs and their power to counteract the defenses of cancer cells, a team of scientists at UCLA engineered CARs to respond to soluble proteins along with surface-bound antigens. In effect, cancer’s primary weapon ends up acting as an instrument of its own destruction.

Since these CARs are engineered, it opens up the possibility of using this method to create cancer immunotherapy treatments for other applications. The UCLA team has already engineered CARs that respond to various soluble proteins, including transforming growth factor (TGF) beta.

Cancer Immunotherapy: Boosting the Body’s Own Immune System

Our individually developed immunotherapy programs focus on restoring the body’s immune system and its natural defense mechanisms. These programs are non-toxic, without the adverse side effects that often accompany chemotherapy and other traditional cancer treatments.

Visit our website for more information.

“Superblood” Engineered to Carry Cancer Fighting Proteins

"Superblood" Engineered to Carry Cancer Fighting Proteins
“Superblood” Engineered to Carry Cancer Fighting Proteins

Super powers are usually the stuff of comic books and movies, but a biotech startup may be turning fiction into reality with the development of “superblood” as a revolutionary new cancer treatment.

“Supercharging” Red Blood Cells

Rubius Therapeutics is working on a program called Red-Cell Therapeutics (RCT), which involves red blood cells that are genetically engineered to fight cancer. Once introduced into a patient’s system, these proteins can replace missing enzymes and help the immune system attack and destroy cancer cells.

RCT has two major advantages that make it a promising breakthrough in cancer treatment:

– The nuclei have been removed from these cells so they can’t be recognized by the immune system, leaving them free from interference so they can do their job.

– Red blood cells travel throughout the entire body, so RCT is able to easily reach any affected organs or tissues.

Thanks to these two features, RCT has the potential to treat patients without the need for an individually developed solution.

What’s Next?

Initially, Rubius Therapeutics generated $120 million from investors. The company recently raised an additional $100 million for a total of nearly a quarter of a billion dollars in less than one year. According to Rubius president Torben Straight Nissen, this funding will help accelerate RCT development for quicker delivery to the end users.

Issels®: The Leader in Immunotherapy Cancer Treatments

Much like RCT, cancer treatment at Issels® is designed to boost the immune system’s ability to attack and kill cancer cells. Contact us to learn more about cancer vaccines and other programs we have used to help patients achieve long-term remission.

No More Biopsies – MRI Recommended for Prostate Cancer Screening

No More Biopsies - MRI Recommended for Prostate Cancer Screening
No More Biopsies – MRI Recommended for Prostate Cancer Screening

The collaborative efforts of a multi-institutional study published by JAMA Oncology is changing prostate cancer treatment protocols. Potential prostate cancer patients may no longer need to line up for biopsies. Instead, MRI-based prediction models are offering a new risk assessment option.

Bye-Bye Biopsy
In the study, researchers from the National Cancer Institute, University of Chicago, and University of Alabama at Birmingham found evidence that the inclusion of an MRI for prostate cancer patients can be used as a biomarker to decrease unnecessary biopsies. It was also determined that the MRIs helped maintain a high rate of diagnoses for clinically significant prostate cancers.

Hello MRI
Based on the data collected, the research points to MRI-based models as further offering the benefit of lower false-positive rates than the baseline model. This means 18% fewer men would be subject to unnecessary biopsies subsequent to false-positive diagnosis.

Next Destination: Improved Cancer Treatment
Co-Author of the study, UAB Department of Urology Assistant Professor and UAB Comprehensive Cancer Center Associate Scientist Soroush Rais-Bahrami, M.D., points to the data’s far-reaching implications. The imaging biomarker is expected to optimize patient selection, as well as allow for the more accurate determination of risk factors and stratification.

What’s more, it will provide physicians with the opportunity to potentially reduce prostate cancer morbidity by enabling a more timely and accurate diagnosis, and thus a faster, more individualized treatment response for prostate cancer treatment patients.

Looking for an alternative approach to cancer treatment? Issels® has you covered. Contact us to learn more about our individualized, non-toxic immunotherapy options. Bring your body back to health with the help of Issels® today.

New Cancer Treatments May Be Studied After Gene Breakthrough Research for Breast Cancer

New Cancer Treatments May Be Studied After Gene Breakthrough Research for Breast Cancer
New Cancer Treatments May Be Studied After Gene Breakthrough Research for Breast Cancer

In the most comprehensive breast cancer treatment study of its kind to-date, scientists may have uncovered the potential for new breast cancer treatment therapies, and possibilities for the development of new drugs aimed at preventing the disease.

More than 100 Genes Linked to Breast Cancer Revealed
After discovering a bounty of genes linked to breast cancer, scientists may soon be able to develop new genetic tests for predicting breast cancer risk, and using the data obtained, ensure targeted cancer treatment for patients.

Genes Linked to Survival Could Aid in Prevention
Thirty-two additional genes, linked to survival in those with receptor-positive breast cancer, were also uncovered. These are hoped to be used to test new treatments, as well as for providing targeted prevention protocols for those most at-risk of developing breast cancer.

Super Sleuths
In the study, funded by Breast Cancer Now, scientists from the Institute of Cancer Research in London used a new genetic technique called ‘Capture Hi-C’ to analyze how genes interacted with 33 DNA regions known to play a role in breast cancer. Of the 110 genes identified in the study, the majority had not been previously linked to breast cancer, providing fresh new insight for those striving to develop improved cancer treatment regimens.

A Vital Piece to Puzzling Out the Disease
The findings are seen as integral to unraveling how genetic changes in the building blocks of the body’s DNA influence breast cancer risk, providing a key piece to solving the cancer puzzle.

Puzzling out your cancer treatment options? Discover the path to improved health with Issels® individualized cancer treatment protocols today.

Individualized Cancer Treatment